Results 261 to 270 of about 1,276,748 (319)

Real‐life implementation of guideline‐recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE‐HF

European Journal of Heart Failure, EarlyView.
Primary results of TITRATE‐HF. GRMT, guideline‐recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. Abstract Aims Guideline‐recommended medical therapy (GRMT) improves outcomes in heart failure (HF) with reduced ejection fraction (HFrEF), yet implementation ...
Jishnu Malgie, Mariëlle I. Wilde, Stefan Koudstaal, Robert Denham, Carlos A. da Fonseca, Henk P. Swart, Clara E.E. van Ofwegen, Ayten Yilmaz, Ron Pisters, Gerard C.M. Linssen, Nikola Faber, Loek van Heerebeek, Julio E.C. van de Swaluw, Rudolf A. de Boer, Hans‐Peter Brunner‐La Rocca, Jasper J. Brugts   +15 more
wiley   +1 more source

Exercise intolerance with ageing: Major role for vascular dysfunction? [PDF]

Exp Physiol
Poole DC, Gaesser GA.
europepmc   +1 more source

Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial

European Journal of Heart Failure, EarlyView.
Summary of the change in left ventricular systolic and diastolic parameters from baseline to 12 months in patients with permanent atrial fibrillation (AF) and a left ventricular ejection fraction (LVEF) ≥50%. P‐values indicate the significance of the adjusted mean difference of the parameters at 12 months between the beta‐blocker and digoxin arm. E/e′,
Karina V. Bunting, Asgher Champsi, Simrat K. Gill, Khalil Saadeh, A. John Camm, Mary Stanbury, Sandra Haynes, Jonathon N. Townend, Richard P. Steeds, Dipak Kotecha, on behalf of the RAte control Therapy Evaluation in Permanent Atrial Fibrillation (RATE‐AF) Trial Group   +10 more
wiley   +1 more source

247 Exercise intolerance in children with cystic fibrosis: a prevalence study

, 2017
G. Arriba de la Fuente, Giuseppe D’Agostino, F. Rentería, G. Rosa Diez   +3 more
openalex   +1 more source

Distinct blood volume and left ventricular adaptation to severe obesity in middle‐aged adults at risk for heart failure

European Journal of Heart Failure, EarlyView.
Obesity, blood volume and ventricular remodelling. BMI, body mass index; DEXA, dual‐energy X‐ray absorptiometry; IR, increased risk; LVEDV, left ventricular end‐diastolic volume; LVEDVi, left ventricular end‐diastolic volume index. Created in BioRender. Wakeham, D.
Joseph Campain, Denis J. Wakeham, Katrin Dias, James P. MacNamara, Mitchel Samels, Erin J Howden, Graeme Carrick‐Ranson, Michinari Hieda, Benjamin D. Levine, Satyam Sarma, Christopher M. Hearon Jr   +10 more
wiley   +1 more source

European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure

European Journal of Heart Failure, EarlyView.
The patient with SMR: From diagnostic assessment to treatment. Secondary mitral regurgitation (SMR) is highly prevalent in patients with heart failure (HF), associated with poor prognosis, and its treatment is typically preceded by implementing pharmacotherapy for HF as well as cardiac resynchronization therapy.
Christos Iliadis, Marianna Adamo, Volker Rudolph, Nicole Karam, Ralph Stephan von Bardeleben, Stefan D. Anker, Victoria Delgado, Jörg Hausleiter, Hannah Kempton, Marco Metra, Michael Böhm, Stephan Baldus   +11 more
wiley   +1 more source

Mechanisms underlying exercise intolerance in Long COVID: an accumulation of multi-system dysfunction

, 2023
Jamieson A, Saikhan LA, Alghamdi L, Howes LH, Purcell H, Hillman T, Heightman M, Treibel T, Orini M, Bell R, Scully M, Hamer M, Chaturvedi N, Montgomery H, Hughes AD, Astin R, Jones S.   +16 more
europepmc   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and of the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA has expanded therapeutic options for this population. This expert consensus
Luca Monzo, Gianluigi Savarese, Wilfried Mullens, Amr Abdin, Biykem Bozkurt, Ovidiu Chioncel, Seif El Hadidi, Thomas M. Gorter, Riccardo M. Inciardi, Mark C. Petrie, Gabriele G. Schiattarella, Davide Stolfo, Marco Metra, Nicolas Girerd   +13 more
wiley   +1 more source

Cardiac dysfunction in dialysing adults with end-stage kidney disease is associated with exercise intolerance: A pilot observational study. [PDF]

Physiol Rep
Antoun J, Shepherd AI, Corbett J, Sangala NC, Lewis RJ, Lane E, Saynor ZL.   +6 more
europepmc   +1 more source